Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) have been assigned a consensus rating of “Buy” from the sixteen brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $118.00.
A number of research firms have recently weighed in on SRPT. The Goldman Sachs Group dropped their target price on Sarepta Therapeutics from $181.00 to $155.00 and set a “buy” rating on the stock in a report on Tuesday. Zacks Investment Research downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating and set a $81.00 price target for the company. in a research report on Tuesday, April 26th. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 21st. Morgan Stanley decreased their price target on Sarepta Therapeutics from $77.00 to $74.00 and set an “equal weight” rating for the company in a research report on Thursday, May 19th. Finally, Royal Bank of Canada increased their price target on Sarepta Therapeutics from $145.00 to $150.00 and gave the company an “outperform” rating in a research report on Wednesday, March 2nd.
Shares of Sarepta Therapeutics stock opened at $70.90 on Friday. Sarepta Therapeutics has a one year low of $61.28 and a one year high of $101.24. The company has a debt-to-equity ratio of 1.28, a current ratio of 5.56 and a quick ratio of 5.13. The stock’s 50-day moving average is $76.08 and its 200 day moving average is $78.51. The firm has a market cap of $6.20 billion, a price-to-earnings ratio of -16.72 and a beta of 1.29.
Several institutional investors have recently bought and sold shares of the company. Arizona State Retirement System boosted its holdings in shares of Sarepta Therapeutics by 0.7% in the third quarter. Arizona State Retirement System now owns 20,643 shares of the biotechnology company’s stock worth $1,909,000 after acquiring an additional 134 shares during the period. M&T Bank Corp boosted its stake in Sarepta Therapeutics by 2.1% during the fourth quarter. M&T Bank Corp now owns 6,966 shares of the biotechnology company’s stock valued at $627,000 after buying an additional 140 shares during the period. Sigma Planning Corp boosted its stake in Sarepta Therapeutics by 1.6% during the fourth quarter. Sigma Planning Corp now owns 13,780 shares of the biotechnology company’s stock valued at $1,241,000 after buying an additional 220 shares during the period. Sit Investment Associates Inc. boosted its stake in Sarepta Therapeutics by 0.5% during the first quarter. Sit Investment Associates Inc. now owns 41,415 shares of the biotechnology company’s stock valued at $3,235,000 after buying an additional 225 shares during the period. Finally, Advisors Asset Management Inc. boosted its stake in Sarepta Therapeutics by 1.0% during the fourth quarter. Advisors Asset Management Inc. now owns 23,780 shares of the biotechnology company’s stock valued at $2,141,000 after buying an additional 229 shares during the period. 81.43% of the stock is owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile (Get Rating)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.
- Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT)
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
- Should Dollar General or Dollar Tree Give Investors a Case of FOMO?
- Genesco Pops On Earnings But Don’t Expect A Rally
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.